Increased Expression of the Multimerin-1 Gene in α-Synuclein Knokout Mice by Chaprova, K. D. et al.
ISSN 0012-4966, Doklady Biological Sciences, 2020, Vol. 494, pp. 260–263. © Pleiades Publishing, Ltd., 2020.
Russian Text © The Author(s), 2020, published in Doklady Rossiiskoi Akademii Nauk. Nauki o Zhizni, 2020, Vol. 494, pp. 537–540.
GENERAL BIOLOGYIncreased Expression of the Multimerin-1 Gene 
in α-Synuclein Knokout Mice
K. D. Chaprova,b,*, V. V. Goloborshchevab,c, T. V. Tarasovaa,b, E. V. Teterinaa,
M. V. Korokind, V. O. Soldatovd, M. V. Pokrovskiyd, V. G. Kucheryanuc,
Corresponding Member of the RAS S. G. Morozovc, and R. K. Ovchinnikova
Received June 10, 2020; revised June 25, 2020; accepted June 25, 2020
Abstract—Multimerin-1 (Mmrn-1) is a soluble protein, also known as elastin microfibril interfacer 4 (EMI-
LIN-4), found in platelets and in the endothelium of blood vessels. Its function and role in pathology are still
not fully understood. Genetic modifications in alpha-synuclein gene (Snca) locus that mapped 160 Kb apart
from Mmrn-1 in mouse genome, could weigh with regulatory elements of Mmrn-1 gene. We have studied the
Mmrn-1 expression in brain cortex of three mouse lines with Snca knock-out: B6(Cg)-Sncatm1.2Vlb/J,
B6;129-Sncatm1Sud/J, and B6;129X1-Sncatm1Rosl/J. The 35-fold increase for Mmrn-1 mRNA level have been
found in B6;129X1-Sncatm1Rosl/J mice that carry in their genome foreign sequences including bacterial gene
neo and a strong promoter of a mouse phosphoglycerate kinase (Pgk1) oriented towards Mmrn-1 gene. This
effect on regulatory elements of Mmrn-1 gene as a result of modifications in Snca locus should be taken into
consideration when using B6;129X1-Sncatm1Rosl/J line, that is widely applied for study of neurodegeneration
mechanisms.
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DOI: 10.1134/S0012496620050014Physiological functions of the high-molecular
weight soluble protein multmerin-1 (Mmrn-1) also
known as elastin microfibril interfacer 4 (EMILIN-4)
are not completely known. Spontaneous deletion of
the gene locus containing the gene encoding Mmrn-1
does not result in any specific phenotype in
C57BL/6j-OlaHsd mice. This allows the conclusion
that the absence of the Mmrn-1 gene can be compen-
sated during embryogenesis [1]. However, detailed
analysis of bone tissue from C57BL/6J-OlaHsd mice
performed by the microcomputer tomography (μCT)
method revealed the reduced weight of spongy sub-26
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*e-mail: chaprov@ipac.ac.rustance of the epiphyses of tubular bones, and histolog-
ical study on the cellular composition of bones showed
an increased content of osteoblasts with decreased
mineralization [2]. This observation together with rel-
atively high expression of the Mmrn-1 gene in bone tis-
sue made it possible to study the involvement of
Mmrn-1 in metabolic processes in osteoblasts and
during bone formation. High content of Mmrn-1 is
also present in blood vessels endothelium and α-gran-
ules of platelets. It is synthesized at a fairly high level in
megakaryocytes and was detected on the surface of
activated platelets in combination with von Willebrand
factor [3].
In mice with deletion of the Mmrn-1 locus, the
changes in the hemostasis system were observed
including impaired platelets aggregation and clot for-
mation and addition of multimerin in experiments in
vitro prevented these impairments [4]. In blood
plasma, Mmrn-1 cannot be detected using routine
methods; however, the increased level of this protein
in the cellular fraction of blood from acute myeloge-
nous leukemia (AML) patients is correlated with low
probability of remission, higher risk of disease recur-
rence, and low survival of patients [5].0
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Fig. 1. Comparative analysis of the expression levels of the
Mmrn-1 gene in three mouse strains with α-synuclein gene
knockout. Content of Mmrn-1 mRNA was measured using
quantitative real-time RT-PCR in the cerebral cortex of
B6;129X1-Sncatm1Rosl/J (AbKO), B6;129-Sncatm1Sud/J
(ТаКО), and B6(Cg)-Sncatm1.2Vlb/J (delta f lox KO) mice
and control wild type (WT) mice. Data are presented as
M ± SEM; n = 6 for each group; ** p < 0.01 for AbKO
group versus other groups according to one-way ANOVA
followed by Tukey’s post hoc test.
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flox KOExperimental studies on impairments of Mmrn-1
functions are mostly performed using the C57BL/6J-
OlaHsd mouse strain [6]. In the genome of these
mice, spontaneous deletion of a long 350 kbp fragment
[1] includes both α-synuclein (Snca) and Mmrn-1 genes
located close to each other at a distance of about 160 kbp.
Α-synuclein (a-syn) is an important constituent of
Lewi bodies, which plays a key role in pathogenesis of
Parkinson’s disease; therefore, several mouse strains
with genetic modifications of the Snca locus were
developed independently [7].
It is possible that the introduced modifications
may affect other regions of genome in close vicinity. In
the present study, we compared the levels of Mmrn-1
expression in three mouse strains with Snca deletion,
such as B6;129X1-Sncatm1Rosl/J (AbKO) provided by
Rosental’s laboratory [8], B6;129-Sncatm1Sud/J
(ТаКО), provided by Sudhof’s laboratory [9], and
B6(Cg)-Sncatm1.2Vlb/J (delta f lox KO) provided by
Buchman’s laboratory [10, 11].
To find out whether different modifications of the
Snca locus can affect the expression of the Mmrn-1
gene located only 160 kbp from the Snca, we studied
the content of Mmrn-1 mRNA in the cerebral cortex
using the real-time RT-PCR method.
Total RNA was extracted from the cortical samples
of three-month-old male mice using RNeasy Plus
Mini kits (Qiagen, Germany) according to the manu-
facturer’s protocol. Two micrograms of purified RNA
were used for the synthesis of a complementary DNA
chain in the reverse transcription reaction and subse-
quent amplification with qPCRmix-HS SYBR reagentsDOKLADY BIOLOGICAL SCIENCES  Vol. 494  2020(Evrogen, Russia) according to the manufacturer’s
real-time protocol using a Bio Rad CFX 96 amplifier
(Bio Rad, United States). The following primers were
used: Mmrn-1 forward (5'-GGACACTGGCTCT-
CATTTAC-3') and Mmrn-1 reverse (5'-CAG-
CATTGGATGTCTTCTGAG-3'). The glyceralde-
hydes-3-phosphate dehydrogenase (GAPDH) gene
was used as a house-keeping gene. The following
primer sequences were used: q_m_GAPDH for-
ward (5'-CACTGAGCATCTCCCTCACA-3') and
q_m_GAPDH reverse (5'-GTGGGTGCAGC-
GAACTTTAT-3').
We estimated the relative levels of Mmrn-1 expres-
sion in three mouse strains with Snca gene knockout
and found that the expression level was 35-fold ele-
vated in the AbKO mice as compared to the expression
level in the cortex of control wild type mice whereas in
the delta f lox KO and TaKO mice it was similar to that
observed in the control mice (Fig. 1). The technology
of designing the studied knockout strains included the
use of embryonic stem cells at the stage of homologous
recombination of the α-synuclein locus with subse-
quent selection of clones based on the production of
the bacterial gene neo introduced in the target cassette.
At the same time, direct modifications of the
sequences in the vicinity to the Snca gene were differ
(Fig. 2). In the AbKO strain, after deletion of the sec-
ond and third α-synuclein exons with adjacent
sequences (size of deletion is about 3.2 kbp) the
modified locus contained a fragment of the plasmid
pGT-N39 vector of 1.9 kbp in size, which carried a
coding sequence of the neo gene under the mouse
phosphoglycerate kinase Pgk1 gene promoter (Fig. 2).
In the knockout TaKO strain, the second and third
Snca exons with adjacent sequences were also deleted
and the size of deletion was 3.9 kbp. The foreign
sequence remained in the modified genomic locus
carried a fragment of pTK-Neo3a plasmid, containing
the neo gene under the control of the mouse subunit A
of polymerase II Polr2a gene promoter (Fig. 2).
It is important that the orientation of the neo cas-
sette in the genomes of the AbKO and TaKO strains
were differed. In the AbKO mice, the neo gene was
located more distal relative to the Snca gene and ori-
ented in reverse direction relative to the modified
gene. In the genome of the TaKO mice, the neo cas-
sette promoter is located more proximal relative to the
Snca promoter and oriented in the same direction
(Fig. 2). In the third strain used in the present study,
the delta f lox KO mice, deletion of the Snca gene was
associated with minimal locus modifications. From
the mouse genome the third exon was deleted contain-
ing the START codon and a small fragment of the
adjacent intronic sequence of 1.1 kbp in size that is
substantially less than in the AbKO or TaKO strains.
Furthermore, the neo gene and other important for-
eign sequences were deleted from the modified locus
of the knockout mice. The only introduced insertion
262 CHAPROV et al.
Fig. 2. Scheme of modifications of the Snca locus in the knockout mouse strains. The foreign sequences of neo gene, LoxP site,
and phosphoglycerate kinase (Pgk1) gene and subunit A of polymerase II (Polr2a) gene promoters, introduced into the mouse
genome are colored. Arrows indicate the transcription directions.
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flox KOleft in the genome of the delta f lox KO mice was the
LoxP site with a size of 34 bp (Fig. 2).
These data point that the functionally active pro-
moter of the pGT-N39 cassette in the genome of the
AbKO mice [8] oriented to Mmrn-1 could activate the
regulatory sequences of this gene. In TaKO mice, the
promoter of the pTK-Neo3a vector oriented in the
opposite direction from the Mmrn-1 gene [9] exhibited
significantly lower effect on the expression of this
gene. In the novel knockout delta flox KO mice [10, 11],
the expression of the Mmrn-1 gene practically did not
differ from its expression in the nonmodified genome
of the wild type mice on the same genetic background
(Fig. 1).
Bioinformatic analysis revealed that potential reg-
ulatory sequences are located between the Snca and
Mmrn-1 genes, and within the Mmrn-1 introns there
are two enhancers and two binding sites for the CTCF
transcription repressor, which is involved in the regu-
lation of chromatin architecture and delimits eu- and
heterochromatin [12].
Our data allow us to assume with a high degree of
probability that impairments in the functioning of reg-
ulatory elements of the genome are the cause of altered
expression of Mmrn-1 in the AbKO mice.
Despite the fact that the AbKO strain of knockout
mice (B6;129X1-Sncatm1Rosl/J) is widely used in labo-
ratories around the world to study neurodegeneration,
the detailed analysis of expression level of Mmrn-1 in
these mice was not performed until now.
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